Rhythm Biosciences Ltd. (AU:RHY) has released an update.
Rhythm Biosciences Ltd, an Australian firm specializing in pioneering cancer diagnostic technologies, has successfully closed a shortfall offer related to their recent rights issue, raising a total of $2,745,416. The company expressed gratitude to both new and existing shareholders for their participation. This capital raise is aimed at advancing the development and distribution of their ColoSTAT® Test-Kit for early detection of colorectal cancer, which is based on significant research and has international patent protection.
For further insights into AU:RHY stock, check out TipRanks’ Stock Analysis page.
